OPKO Health (NASDAQ:OPK) Given New $1.50 Price Target at Barrington Research

OPKO Health (NASDAQ:OPK) had its price objective lowered by analysts at Barrington Research from $2.25 to $1.50 in a report released on Monday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Barrington Research’s price target would suggest a potential upside of 25.52% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OPKO Health currently has a consensus rating of “Hold” and an average target price of $2.03.

OPKO Health Stock Performance

Shares of OPKO Health stock traded down $0.01 on Monday, hitting $1.20. 758,031 shares of the company’s stock were exchanged, compared to its average volume of 2,907,324. The company has a 50-day simple moving average of $1.27 and a 200-day simple moving average of $1.36. The stock has a market capitalization of $917.40 million, a PE ratio of -3.98 and a beta of 1.47. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.30% and a negative net margin of 37.19%.The firm had revenue of $148.50 million during the quarter, compared to analyst estimates of $139.76 million. During the same period in the prior year, the business posted $0.01 EPS. OPKO Health’s revenue was down 19.1% on a year-over-year basis. As a group, equities analysts anticipate that OPKO Health will post -0.25 EPS for the current year.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPK. Geode Capital Management LLC raised its stake in shares of OPKO Health by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 67,973 shares in the last quarter. Millennium Management LLC grew its holdings in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after acquiring an additional 3,600,378 shares during the period. UBS Group AG lifted its position in OPKO Health by 12.1% during the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 577,248 shares during the period. Finally, AWM Investment Company Inc. grew its stake in OPKO Health by 8.1% during the 2nd quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,640,000 after purchasing an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.